Patents Represented by Attorney, Agent or Law Firm Henry D. Coleman
  • Patent number: 7708991
    Abstract: The present invention relates to compositions and methods for treating cancer, especially epithelial and eutopic cancers using inhibitors of H-HCG or ?-H-HCG, as well as vaccines for use in oncostasis or reducing the likelihood of recurrence of cancer after remission. In addition, the present invention provides a method for reducing the likelihood that a woman will become pregnant or that an unwanted pregnancy may be terminated.
    Type: Grant
    Filed: February 15, 2005
    Date of Patent: May 4, 2010
    Assignee: STC.UNM
    Inventor: Laurence A Cole
  • Patent number: 7678365
    Abstract: This invention relates generally to compositions and methods useful for oral hygiene rinses, and more specifically to oral rinses in which the antimicrobial activity of chlorous acid is supplemented by that of lactic acid as one of a combination of antimicrobial acids, preferably acids which serve to partially convert chlorite ion to chlorous acid.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: March 16, 2010
    Inventor: Robert D. Kross
  • Patent number: 7666683
    Abstract: The present invention relates to a novel method of determining the existence of a normal pregnancy which has a high likelihood of culminating in a term pregnancy, by measuring hyperglycosylated hCG in a pregnant woman and comparing the concentration of measured hyperglycosylated hCG with a predetermined value. A measurement of hyperglycosylated hCG above the predetermined value, for example, about 13 ng/ml, is evidence of a high likelihood of a normal pregnancy. A measurement below the predetermined value is evidence of an abnormal pregnancy (ectopic pregnancy or miscarriage). Further analysis of the patient in the event that the measurement falls below the predetermined value is made by intravaginal or abdominal ultrasound to determine whether or not the pregnancy is ectopic or will likely result in a spontaneous abortion (miscarriage).
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: February 23, 2010
    Assignee: STC.UNM
    Inventor: Laurence A. Cole
  • Patent number: 7615542
    Abstract: The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R1 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nuleocoside reverse transcriptase inhibitors (NRTI), non-nucloeoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others.
    Type: Grant
    Filed: December 8, 2003
    Date of Patent: November 10, 2009
    Assignees: University of Georgia Research Foundation, Inc., Emory UNiversity
    Inventors: Chung K. Chu, Raymond F. Schinazi
  • Patent number: 7589078
    Abstract: The present invention relates to compounds according to the general formula: wherein B is or and the remaining variables are defined in the specification, and compositions comprising the compounds. The compounds are useful as anti-viral agents in viral therapy.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: September 15, 2009
    Assignee: Yale University
    Inventors: Yung-chi Cheng, Hiromichi Tanaka, Masanori Baba
  • Patent number: 7572639
    Abstract: A method for predicting pregnancy outcome includes measuring blood levels of hCG-hg and progesterone in a pregnant woman, determining a rate of change of progesterone levels from the blood measurements, determining at least a qualitative direction of change of hCG-hg levels from the blood measurements, comparing the determined rate of change of progesterone levels with a pre-established reference value, and determining at least a qualitative likelihood of a term pregnancy and a failed pregnancy for the woman from the qualitative direction of change of hCG-hg levels and the determined rate of change of progesterone levels relative to the pre-established reference value. The rate of change of progesterone is determined by formula as a number of days for progesterone to double.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: August 11, 2009
    Assignee: STC.UNM
    Inventors: Laurence A. Cole, Jaime M. Riley, Francis W. Byrn
  • Patent number: 7569643
    Abstract: The present invention relates to novel polymeric compositions based upon An(BCB)An polyester/polyether multi-blocks. Compositions according to the present invention exhibit unexpectedly exceptional reverse thermal gellation properties and in certain cases, relatively low viscosities at approximately room temperature and extremely high viscosities at temperatures above room temperature (preferably at approximately physiological or body temperature, i.e., within a temperature range of about 32-40° C.). Compositions according to the present invention may be used advantageously in applications which make use of their reverse thermal gellation properties. Preferred applications for use of the present compositions include, for example, medical applications which make advantageous use of the inherent composition characteristic of being of relatively low viscosity at room temperature and much higher viscosity at elevated temperatures, especially body temperature.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: August 4, 2009
    Assignee: Synthemed, Inc.
    Inventors: Daniel Cohn, Avraham Levi
  • Patent number: 7569573
    Abstract: A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: August 4, 2009
    Assignee: The University of Georgia Research Foundation, Inc.
    Inventors: Vasu Nair, Guochen Chi, Vinod R. Uchil
  • Patent number: 7531354
    Abstract: The present invention relates to methods for producing feeder cell-free neuroprogenitor cells (preferably adherent) from embryonic stems cells, preferably human embryonic stem cells, the feeder cell-free neuroprogenitor cells, preferably human cells themselves, as well as methods for producing feeder cell-free samples of neuronal cells, preferably adherent human neuronal cells and the feeder cell-free neuronal cells themselves. Pharmaceutical compositions and methods of treating neurodegenerative diseases as well as the use of the described cells in assay systems is also described.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: May 12, 2009
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Steve Stice, Soojung Shin, Sujoy Dhara
  • Patent number: 7521568
    Abstract: Enantiopure substituted 4-deoxypentenosides (4-DPs) and related dihydropyrans (DHPs) are prepared from common carbohydrates via a novel process. The 4-DPs and related DHPs are amenable to a broad range of stereoselective transformations and are used as synthetic intermediates to prepare a variety of enantiopure tetrahydropyrans (THPs), including rare or exotic sugars and other complex THPs of commercial or medicinal value. In one embodiment of the instant invention, 4-DPs are converted to L-sugars in a novel process that offers distinct advantages over known synthetic methods.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: April 21, 2009
    Assignee: Purdue Research Foundation
    Inventors: Alexander Wei, Fabien P. Boulineau
  • Patent number: 7501535
    Abstract: The invention provides novel six and seven-carbon termini-differentiated polypropionate stereotetrads and stereopentads useful in syntheses of natural products. The invention also provides a novel alkylative sulfenylation-desulfonylation process that efficiently transforms enantiopure epoxyvinyl sulfones to syn and anti dienylsulfides in two operations.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: March 10, 2009
    Assignee: Purdue Research Foundation
    Inventors: Philip L. Fuchs, David J. Meyers, Eduardo Torres, Taesik Park, In C. Kim, Yuzhong Chen, Douglas Lantrip, Jerry B. Evarts, Jr.
  • Patent number: 7435555
    Abstract: A target asparagine residue of HIF 1 alpha and 2 alpha is hydroxylated at high oxygen tension to render HIF as a weak transcription factor. An asparagine hydroxylase hydroxylation motif and binding motif is proposed. A method of screening for agonists or antagonists of an asparagine hydroxylase is also proposed and involves mixing peptides or proteins having the hydroxylation and or the binding motif with asparagine hydroxylase and a candidate agonist or antagonist. The extent of inhibition or enhancement of binding; level of asparagine hydroxylation or transactivation may be measured depending on the nature of the protein or peptide. Additionally altered proteins resistant to hydroxylation are described as are nucleic acids encoding such proteins.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: October 14, 2008
    Assignee: Adelaide Research and Innovation Pty Ltd.
    Inventors: Murray L Whitelaw, David Lando, Daniel J Peet, Jeffrey J Gorman, Sarah Linke
  • Patent number: 7432303
    Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: October 7, 2008
    Assignees: James and Emory University
    Inventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
  • Patent number: 7425616
    Abstract: The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: September 16, 2008
    Assignee: STC.UNM
    Inventors: Terry W. Du Clos, Carolyn Mold
  • Patent number: 7405317
    Abstract: Novel phosphate-bearing prodrugs of sulfonyl hydrazines have the formula presented below. Pharmaceutical compositions and uses thereof in the treatment of cancer are claimed. The aforementioned prodrugs include enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates and metabolites from all stages. The aforementioned prodrugs are preferentially activated in hypoxic tumors and can be given either alone, or in combination with other anticancer agents or with phototheraphy or radiotherapy. where R is C1-C10 alkyl or haloalkyl; R? and R? are each independently C1-C10 alkyl; R1 is CH3; and X is O; or a pharmaceutically acceptable salt, solvate, polymorph or metabolite thereof.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: July 29, 2008
    Assignee: Vion Pharmaceuticals Inc.
    Inventors: Xu Lin, Ivan King, Michael F. Belcourt, Terrence W. Doyle
  • Patent number: 7371897
    Abstract: Provided is a novel preparation method of (Z)-7-chloro-((S)-2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid represented by the following formula (1), a key intermediate of cilastatin used as a supplement to imipenem. The novel preparation method of the invention produces a pure (Z)-7-chloro-((S)-2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid, a key intermediate of cilastatin, by selective hydrolysis of E isomers.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: May 13, 2008
    Assignee: Wischem Co., Ltd.
    Inventors: Yang Rai Cho, Young Ji Shim, Eon Cheol Koo, Seon Yi Jeong, Byung Hwan Kim
  • Patent number: 7329438
    Abstract: The present invention is directed to a method for producing a high gloss coating on a printed surface. In the present method, an aqueous coating composition is deposited onto a surface to be printed using a blanket roller coating face which is a low energy, non-stick, smooth surface profile. In the present method, simultaneous with the deposition of aqueous coating onto a substrate, or shortly thereafter, pressure either alone or in combination with heat may be applied to the coating in order to create a substantially tack-free surface conforming to the surface of the coating face. By using a highly polished coating face, high gloss coatings may be readily obtained using this methodology in a number of traditional printing techniques including wet trap inline sheet-fed printing, heat-set offset printing, dry trap inline flexographic printing, offset web-fed printing and gravure printing.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: February 12, 2008
    Inventors: Joseph Frazzitta, Frank V. Frazzitta
  • Patent number: 7314760
    Abstract: The invention provides prenatal screening methods for Down's syndrome. Specifically, the methods of the invention comprise determining the amount of hyperglycosylated human chorionic gonadotropin (hCG) charge isoforms in a biological sample from a pregnant woman and comparing the amount of highly acidic and less acidic isoforms with those found in a sample taken from a pregnant woman carrying a normal fetus. The methods of the invention can be employed during any stage of pregnancy.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: January 1, 2008
    Assignee: STC. UNM
    Inventors: Laurence A Cole, Jaime M Riley
  • Patent number: 7312246
    Abstract: The present invention relates to compounds and pharmaceutical compositions which are proteonaimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention. In particular, the invention relates to treatment of viral infections using terphenyl derivatives.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: December 25, 2007
    Assignee: Yale University
    Inventors: Andrew D. Hamilton, Justin Ernst, Brendan Orner
  • Patent number: 7304092
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions and methods for treating tumors, cancer and hyperproliferative diseases including psoriasis, genital warts and hyperproliferative cell growth diseases, including hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus.
    Type: Grant
    Filed: November 11, 2003
    Date of Patent: December 4, 2007
    Assignee: Yale University
    Inventors: David J. Austin, Viet-Ahn A. Nguyen, Doris Pupowicz, Albert Deisseroth, Tao Wang, Enrica Lerma